23:53 , Jul 10, 2019 |  BC Extra  |  Politics & Policy

CMS’s new CKD payment models could be mixed bag for drug companies

A set of five different payment models announced by the Centers for Medicare & Medicaid Services for patients with chronic kidney disease or end-stage renal disease could be a boon for companies that have taken...
06:04 , Jun 10, 2019 |  BC Extra  |  Company News

With industry's growing kidney momentum, Everest begins building kidney portfolio

Everest Medicines added its first therapy to a planned renal portfolio on Monday through a deal with Calliditas. The therapy, Nefecon (PL-56, Nefigan), is in the Phase III Nefigard trial to treat IgA nephropathy. It...
14:31 , May 8, 2019 |  BC Extra  |  Company News

Gilead’s Goldfinch deal signals renewed optimism in kidney therapies

In the latest sign of that the kidney is regaining attention for drug developers, Gilead has tapped Goldfinch's drug discovery tools to co-develop therapies for diabetic kidney disease and orphan kidney diseases. Goldfinch Biopharma Inc....
01:42 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Tamura reclaims CEO role at Sosei

Sosei Group Corp. (Tokyo:4565) said Peter Bains will step down as president and CEO and resign as director on Dec. 31. Executive Chairman, founder and former CEO Shinichi Tamura will replace Bains, effective Jan. 1....
21:33 , Mar 13, 2018 |  BC Extra  |  Company News

Management tracks: Ipsen, Illumina

Ipsen Group (Euronext:IPN; Pink:IPSEY) hired Ivana Magovcevic-Liebisch as EVP and CBO. She was EVP and chief strategy and corporate development officer at Axcella Health Inc. (Cambridge, Mass.). Genomics company Illumina Inc. (NASDAQ:ILMN) hired Phil Febbo...
00:02 , Dec 7, 2017 |  BC Extra  |  Company News

Management Tracks: Sunesis, Vital

Cancer company Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) said President and CEO Daniel Swisher will step down, effective Dec. 31. He will join Jazz Pharmaceuticals plc (NASDAQ:JAZZ) as president and COO. Director Dayton Misfeldt will serve as...
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and...
20:31 , Dec 16, 2016 |  BC Week In Review  |  Financial News

Goldfinch Biopharma completes venture round

Goldfinch Biopharma raised $55 million in a series A round from Third Rock Ventures. Goldfinch Biopharma Inc. , Cambridge, Mass. ...
01:23 , Dec 15, 2016 |  BC Extra  |  Financial News

Kidney newco Goldfinch launches with $55M

Third Rock Ventures launched Goldfinch Biopharma Inc. (Cambridge, Mass.) with a $55 million series A round to develop precision therapies for kidney diseases. The firm was the sole investor. Goldfinch intends to establish a registry...